Amicus Therapeutics Announces Positive Preliminary Results From Ongoing Phase 2 Chaperone-Enzyme Replacement Therapy Study
Amicus Therapeutics (Nasdaq: FOLD), today announced preliminary results from an ongoing, open-label Phase 2 drug-drug interaction study to evaluate the safety and pharmacokinetic effects of two doses of migalastat HCl (150 mg and 450 mg) co-administered with ERT (agalsidase beta or agalsidase alfa) in up to 24 males diagnosed with Fabry disease.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.